Shareholders approve all proposals; board adopts updated director compensation program

Arcutis Biotherapeutics, Inc.

Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
Ernst & Young ratified as independent auditor for fiscal year 2026.
Non-binding advisory vote approved named executive officer compensation.
Revised director comp: $50k base retainer, $350k initial option, annual $350k award (65% options, 35% RSUs).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcutis Biotherapeutics, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2026-06-05 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-05

Exact text from the filing

Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected at the 2026-06-05 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-05

Exact text from the filing

Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-05

Exact text from the filing

Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026

View on SEC.gov

1671 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Arcutis Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-041883

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.